DOT HeartMate 3 Study

Direct Oral Anticoagulant Therapy With the HeartMate 3 LVAD: A Pilot Study

NCT04974684•Institute for Clinical and Experimental Medicine

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

LVAD (Left Ventricular Assist Device) Thrombosis

Interventions

HeartMate 3

Apixaban

Locations

Czechia

Locations (1)

Institute for Clinical and Experimental Medicine

Prague, Czechia

Key Dates

Start Date

April 1, 2022

Primary Completion Date

March 1, 2024

Completion Date

March 1, 2024

Last Updated

August 20, 2024

Sponsors

Lead Sponsor

Institute for Clinical and Experimental Medicine

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 20, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions